Reporter brief
Randomized pilot trial of rapamycin for ovarian aging in women; results not reported
What happened
A prospective, randomized, double-blind, placebo-controlled pilot study was proposed to assess whether low-dose rapamycin could delay ovarian aging in women. Animal studies had suggested rapamycin might slow or reverse age-associated pathways. No results, sample size, or effect sizes were reported in the abstract.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Women
- Design
- Rct
- Sample
- —
- Journal
- Columbia University
- Published
- Dec 26, 2025
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Rapamycin timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.